BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22071662)

  • 1. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
    Silva EG; Paula CR; de Assis Baroni F; Gambale W
    Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulatory effect of voriconazole on the production of proinflammatory cytokines in experimental cryptococcosis in mice with severe combined immunodeficiency.
    Gonçalves Silva E; Marilia de Souza Silva S; Rodrigues Paula C; da Silva Ruiz L; Latercia Tranches Dias A
    J Mycol Med; 2018 Mar; 28(1):106-111. PubMed ID: 29273275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.
    Silva EG; Paula CR; Dias AL; Chang MR; Ruiz Lda S; Gambale V; Prates RA; Ribeiro MS
    Mycopathologia; 2011 Apr; 171(4):261-6. PubMed ID: 20972836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation.
    Fujioka K; Nagai T; Kinoshita Y; Urushihara M; Hamasaki Y; Shishido S; Kagami S
    CEN Case Rep; 2019 Nov; 8(4):261-265. PubMed ID: 31161376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intrathecal administration of liposomal amphotericin B combined with voriconazole in a murine model of cryptococcal meningitis.
    Gazzoni AF; Capilla J; Mayayo E; Guarro J
    Int J Antimicrob Agents; 2012 Mar; 39(3):223-7. PubMed ID: 22226648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection.
    Serena C; Pastor FJ; Mariné M; Rodríguez MM; Guarro J
    J Antimicrob Chemother; 2007 Jul; 60(1):162-5. PubMed ID: 17483143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
    Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
    J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.
    Calvo E; Pastor FJ; Rodríguez MM; Pujol I; Guarro J
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4074-7. PubMed ID: 20625150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.
    Sionov E; Chang YC; Garraffo HM; Dolan MA; Ghannoum MA; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1162-9. PubMed ID: 22155829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P; Dromer F; Lortholary O; Dannaoui E
    Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
    Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
    J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined antifungal therapy against systemic murine infections by rare Cryptococcus species.
    Thomson P; Mayayo E; López-Fernández L; Guarro J; Capilla J
    Mycoses; 2017 Feb; 60(2):112-117. PubMed ID: 27696562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
    Kirkpatrick WR; Coco BJ; Patterson TF
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis.
    Block ER; Bennett JE
    Proc Soc Exp Biol Med; 1973 Feb; 142(2):476-80. PubMed ID: 4570039
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.
    Chandenier J; Adou-Bryn KD; Douchet C; Sar B; Kombila M; Swinne D; Thérizol-Ferly M; Buisson Y; Richard-Lenoble D
    Eur J Clin Microbiol Infect Dis; 2004 Jun; 23(6):506-8. PubMed ID: 15141336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii.
    Mitchell DH; Sorrell TC
    Clin Infect Dis; 1992 May; 14(5):1142-4. PubMed ID: 1600018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of voriconazole in experimental Cryptococcus neoformans infection.
    Mavrogiorgos N; Zaragoza O; Casadevall A; Nosanchuk JD
    Mycopathologia; 2006 Aug; 162(2):111-4. PubMed ID: 16897589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.